KR100584797B1 - 아데노신 수용체 아고니스트 또는 길항제를 포함하는 제약조성물 - Google Patents

아데노신 수용체 아고니스트 또는 길항제를 포함하는 제약조성물 Download PDF

Info

Publication number
KR100584797B1
KR100584797B1 KR1020027003164A KR20027003164A KR100584797B1 KR 100584797 B1 KR100584797 B1 KR 100584797B1 KR 1020027003164 A KR1020027003164 A KR 1020027003164A KR 20027003164 A KR20027003164 A KR 20027003164A KR 100584797 B1 KR100584797 B1 KR 100584797B1
Authority
KR
South Korea
Prior art keywords
adenosine
delete delete
group
iodobenzyl
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020027003164A
Other languages
English (en)
Korean (ko)
Other versions
KR20020038749A (ko
Inventor
니나 피쉬맨
Original Assignee
캔-파이트 바이오파마 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL13186499A external-priority patent/IL131864A0/xx
Application filed by 캔-파이트 바이오파마 리미티드 filed Critical 캔-파이트 바이오파마 리미티드
Publication of KR20020038749A publication Critical patent/KR20020038749A/ko
Application granted granted Critical
Publication of KR100584797B1 publication Critical patent/KR100584797B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020027003164A 1999-09-10 2000-09-08 아데노신 수용체 아고니스트 또는 길항제를 포함하는 제약조성물 Expired - Lifetime KR100584797B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IL131864 1999-09-10
IL13186499A IL131864A0 (en) 1999-09-10 1999-09-10 Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
IL133680 1999-12-23
IL13368099A IL133680A0 (en) 1999-09-10 1999-12-23 Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020067006473A Division KR100674529B1 (ko) 1999-09-10 2000-09-08 아데노신 수용체 아고니스트 또는 길항제를 포함하는 제약조성물

Publications (2)

Publication Number Publication Date
KR20020038749A KR20020038749A (ko) 2002-05-23
KR100584797B1 true KR100584797B1 (ko) 2006-06-02

Family

ID=26323880

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020027003164A Expired - Lifetime KR100584797B1 (ko) 1999-09-10 2000-09-08 아데노신 수용체 아고니스트 또는 길항제를 포함하는 제약조성물
KR1020067006473A Expired - Lifetime KR100674529B1 (ko) 1999-09-10 2000-09-08 아데노신 수용체 아고니스트 또는 길항제를 포함하는 제약조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020067006473A Expired - Lifetime KR100674529B1 (ko) 1999-09-10 2000-09-08 아데노신 수용체 아고니스트 또는 길항제를 포함하는 제약조성물

Country Status (19)

Country Link
US (2) US7064112B1 (https=)
EP (1) EP1261322B1 (https=)
JP (2) JP4980530B2 (https=)
KR (2) KR100584797B1 (https=)
CN (1) CN100358512C (https=)
AU (1) AU782826B2 (https=)
BR (1) BR0013905A (https=)
CA (1) CA2384111C (https=)
DE (1) DE60037277T2 (https=)
DK (1) DK1261322T3 (https=)
ES (1) ES2296637T3 (https=)
HK (1) HK1052653B (https=)
HU (1) HU226913B1 (https=)
IL (1) IL133680A0 (https=)
MX (1) MXPA02002546A (https=)
PL (1) PL199852B1 (https=)
PT (1) PT1261322E (https=)
RU (1) RU2239455C2 (https=)
WO (1) WO2001019360A2 (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL121272A (en) * 1997-07-10 2000-06-01 Can Fite Technologies Ltd Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia
AU2001281817B2 (en) * 2000-06-21 2005-11-24 F. Hoffmann-La Roche Ag Benzothiazole derivatives
US7589075B2 (en) 2001-01-16 2009-09-15 Can-Fite Biopharma Ltd. Use of an adenosine A3 receptor agonist for inhibition of viral replication
US20020115635A1 (en) * 2001-02-21 2002-08-22 Pnina Fishman Modulation of GSK-3beta activity and its different uses
US20040204481A1 (en) * 2001-04-12 2004-10-14 Pnina Fishman Activation of natural killer cells by adenosine A3 receptor agonists
US7049303B2 (en) * 2001-11-07 2006-05-23 Medical Research Council Inhibition of viruses
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
JP2006503574A (ja) * 2002-10-22 2006-02-02 カン−フィテ・バイオファーマ・リミテッド 疾患の状態に関するマーカーとしてのａ３ａｒ
US7087761B2 (en) 2003-01-07 2006-08-08 Hoffmann-La Roche Inc. Cyclization process for substituted benzothiazole derivatives
RS50574B (sr) 2004-05-24 2010-05-07 F. Hoffmann-La Roche Ag. (4-metoksi-7-morfolin-4-il-benzotiazol-2-il)-amid 4-hidroksi-4-metil-piperidin-1-karboksilne kiseline
WO2005117910A2 (en) 2004-05-26 2005-12-15 Inotek Pharmaceuticals Corporation Purine derivatives as adenosine a1 receptor agonists and methods of use thereof
US7825102B2 (en) 2004-07-28 2010-11-02 Can-Fite Biopharma Ltd. Treatment of dry eye conditions
MX2007003271A (es) 2004-09-20 2007-06-05 Inotek Pharmaceuticals Corp Derivados de purina y metodos de uso de los mismos.
EP1799221A1 (en) * 2004-10-15 2007-06-27 Cv Therapeutics, Inc. Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists
ES2309814T3 (es) 2004-11-05 2008-12-16 F. Hoffmann-La Roche Ag Proceso para la obtencion de derivados del acido isonicotinico.
WO2006048884A1 (en) * 2004-11-08 2006-05-11 Can-Fite Biopharma Ltd. Therapeutic treatment of accelerated bone resorption
AU2005336924A1 (en) * 2004-11-22 2007-04-12 King Pharmaceuticals Research & Development, Inc. Enhancing treatment of cancer and HIF-1 mediated disoders with adenosine A3 receptor antagonists
WO2006099972A1 (en) 2005-03-23 2006-09-28 F. Hoffmann-La Roche Ag Acetylenyl-pyrazolo-pvrimidine derivatives as mglur2 antagonists
JP5048675B2 (ja) 2005-09-27 2012-10-17 エフ．ホフマン−ラ ロシュ アーゲー ｍＧｌｕＲ２アンタゴニストとしてのオキサジアゾリルピラゾロ−ピリミジン類
EA015683B1 (ru) 2005-11-30 2011-10-31 Инотек Фармасьютикалз Корпорейшн Производные пурина и способы их применения
BRPI0621052A2 (pt) * 2006-01-27 2012-07-17 Can Fite Biopharma Ltd uso de um agonista de receptor de adenosina a3 (a3ar)
WO2008023362A2 (en) * 2006-08-21 2008-02-28 Can-Fite Biopharma Ltd. Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
JP2010505848A (ja) * 2006-10-06 2010-02-25 ザ トラスティーズ オヴ ザ ユニヴァーシティー オヴ ペンシルバニア 眼内圧を低下させるための種交差性ａ３アデノシン受容体アンタゴニストの効果的送達
GB0625100D0 (en) * 2006-12-15 2007-01-24 Univ Murcia Epigallocatechin-3-gallate compositions for cancer therapy and chemoprotection
US20090088403A1 (en) * 2007-05-07 2009-04-02 Randy Blakely A3 adenosine receptors as targets for the modulation of central serotonergic signaling
TW200914048A (en) * 2007-07-17 2009-04-01 Combinatorx Inc Combinations for the treatment of B-cell proliferative disorders
AU2008276451A1 (en) * 2007-07-17 2009-01-22 Zalicus Inc. Treatments of B-cell proliferative disorders
US20100009934A1 (en) * 2008-06-09 2010-01-14 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
EP2334179A4 (en) * 2008-09-08 2012-09-26 Merck Sharp & Dohme AHCY-HYDROLASE INHIBITOR FOR THE TREATMENT OF HYPERHOMOCYSTEINEMIA
KR20120022919A (ko) 2009-05-17 2012-03-12 캔-파이트 바이오파마 리미티드 안압의 감소를 위한 ａ3 아데노신 수용체 작동제
WO2011010306A1 (en) 2009-07-21 2011-01-27 Ramot At Tel-Aviv University Ltd. A3 adenosine receptor ligands for modulation of pigmentation
WO2011074903A2 (ko) * 2009-12-17 2011-06-23 이화여자대학교 산학협력단 Ａ3 아데노신 수용체 효능제를 포함하는 약제학적 조성물
SG182285A1 (en) 2010-01-11 2012-08-30 Inotek Pharmaceuticals Corp Combination, kit and method of reducing intraocular pressure
US20130045943A1 (en) 2010-03-03 2013-02-21 The Government Of The United States Of America As Represented By The Secretary Of The Department Of A3ar agonists for the treatment of uveitis
EA201290958A1 (ru) 2010-03-26 2013-04-30 Инотек Фармасьютикалз Корпорейшн Способ снижения внутриглазного давления у людей с применением n6-циклопентиладенозина (cpa), производных cpa или их пролекарств
WO2011123518A1 (en) 2010-03-31 2011-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
SG10201913554YA (en) 2011-12-22 2020-03-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
JP2015504088A (ja) * 2012-01-23 2015-02-05 キャン−ファイト バイオファーマ リミテッドＣａｎ−Ｆｉｔｅ ＢｉｏＰｈａｒｍａ Ｌｔｄ． 肝疾患の治療
BR112014018413A8 (pt) 2012-01-26 2017-07-11 Inotek Pharmaceuticals Corp Polimorfos anidros de nitrato de metila [(2r,3s,4r,5r)-5-(6-(ciclopentilamino)-9h-purin-9-il)-3,4-diidroxitetraidrofuran-2-il)] e processos de preparação do mesmo
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US8822460B2 (en) 2012-04-06 2014-09-02 Janssen Pharmaceutica Nv Fused cyclopentyl antagonists of CCR2
CN105358551A (zh) 2012-07-19 2016-02-24 詹森药业有限公司 Ccr2的八氢环戊并吡咯基拮抗剂
KR101971762B1 (ko) 2012-08-09 2019-08-13 캔-파이트 바이오파마 리미티드 성기능장애의 치료에 사용하기 위한 a3 아데노신 수용체 리간드
CA2903114A1 (en) 2013-03-15 2014-09-25 Inotek Pharmaceuticals Corporation Ophthalmic formulations
IL242723B (en) 2015-11-23 2019-12-31 Can Fite Biopharma Ltd A3 adenosine receptor ligand for the treatment of ectopic fat accumulation
EP3445368B1 (en) 2016-04-21 2024-07-17 Astrocyte Pharmaceuticals, Inc. Compounds and methods for treating neurological and cardiovascular conditions
IL254535A0 (en) * 2017-09-17 2017-11-30 Can Fite Biopharma Ltd Adenosine a3 receptor ligand for use in the management of cytokine release syndrome
CN112218638A (zh) 2018-02-09 2021-01-12 阿斯特罗赛特制药公司 用于治疗成瘾和相关病症的化合物和方法
EP3856741A4 (en) 2018-09-26 2022-06-22 Astrocyte Pharmaceuticals, Inc. POLYMORPHOUS COMPOUNDS AND USES THEREOF
IL264112A (en) 2019-01-06 2020-07-30 Fishman Pnina An a3 adenosine receptor ligand for use for reducing level of adipocytes
IT202300014340A1 (it) 2023-07-10 2025-01-10 Consiglio Nazionale Ricerche Trattamento di malattie associate alla disfunzione del gene ocrl.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443836A (en) * 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
WO1995002604A1 (en) * 1993-07-13 1995-01-26 The United States Of America, Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists
US5688774A (en) 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
GB2289218A (en) * 1994-05-06 1995-11-15 Merck & Co Inc Inhibition of TNFalpha production with agonists of the A2b subtype of the adenosine receptor
RU2071770C1 (ru) * 1994-12-14 1997-01-20 Владислав Алексеевич Шматко Способ лечения рака шейки матки и яичников
RU2071771C1 (ru) * 1995-01-11 1997-01-20 Владислав Алексеевич Шматко Способ лечения рака молочной железы
US6211165B1 (en) * 1997-05-09 2001-04-03 The Trustees Of The University Of Pennsylvania Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
IL121272A (en) 1997-07-10 2000-06-01 Can Fite Technologies Ltd Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia
US6048865A (en) * 1997-07-29 2000-04-11 Medco Research, Inc. N6 -substituted-adenosine-5'-uronamides as adenosine receptor modulator
JP2003517423A (ja) * 1997-07-29 2003-05-27 メドコ リサーチ、インコーポレイテッド アデノシンレセプターモジュレーターとしてのｎ６−置換アデノシン−５′−ウロナミド
AU1363699A (en) * 1997-10-23 1999-05-10 National Institute Of Health Methods for reducing ischemic injury of the heart via the sequential administ ration of monophosphoryl lipid a and adenosine receptor agents
CA2316994A1 (en) * 1998-06-08 1999-12-16 Epigenesis Pharmaceuticals, Inc. Composition and method for prevention and treatment of cardiopulmonary and renal failure or damage associated with ischemia, endotoxin release, ards or brought about by administration of certain drugs
US6448253B1 (en) * 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
IL127947A0 (en) 1999-01-07 1999-11-30 Can Fite Technologies Ltd Pharmaceutical use of adenosine agonists
UA72912C2 (uk) * 1999-02-01 2005-05-16 Юніверсіті Оф Вірджінія Патент Фаундейшн Композиція для лікування запальної реакції
IL131096A (en) 1999-07-26 2004-09-27 Can Fite Technologies Ltd Method for preparing a composition derived from muscle tissue

Also Published As

Publication number Publication date
WO2001019360A3 (en) 2002-09-19
MXPA02002546A (es) 2003-07-21
JP4980530B2 (ja) 2012-07-18
JP2007204496A (ja) 2007-08-16
PT1261322E (pt) 2008-01-09
AU6863400A (en) 2001-04-17
DK1261322T3 (da) 2008-04-07
EP1261322A2 (en) 2002-12-04
BR0013905A (pt) 2003-07-15
CN1391468A (zh) 2003-01-15
HUP0203870A2 (hu) 2003-03-28
DE60037277T2 (de) 2008-10-09
KR20020038749A (ko) 2002-05-23
KR20060036490A (ko) 2006-04-28
IL133680A0 (en) 2001-04-30
PL199852B1 (pl) 2008-11-28
EP1261322B1 (en) 2007-11-28
AU782826B2 (en) 2005-09-01
US7064112B1 (en) 2006-06-20
CA2384111C (en) 2008-05-27
HU226913B1 (en) 2010-03-01
RU2239455C2 (ru) 2004-11-10
PL356469A1 (en) 2004-06-28
RU2002109228A (ru) 2004-01-10
HK1052653A1 (zh) 2003-09-26
ES2296637T3 (es) 2008-05-01
CN100358512C (zh) 2008-01-02
JP2003514771A (ja) 2003-04-22
US20060084626A1 (en) 2006-04-20
WO2001019360A2 (en) 2001-03-22
DE60037277D1 (de) 2008-01-10
HUP0203870A3 (en) 2005-07-28
KR100674529B1 (ko) 2007-01-30
CA2384111A1 (en) 2001-03-22
HK1052653B (zh) 2008-08-01

Similar Documents

Publication Publication Date Title
KR100584797B1 (ko) 아데노신 수용체 아고니스트 또는 길항제를 포함하는 제약조성물
US6579857B1 (en) Combination cancer therapy comprising adenosine and deaminase enzyme inhibitors
EP1365776B1 (en) Use of an adenosine a3 receptor agonist for inhibition of viral replication
Bar-Yehuda et al. Resistance of muscle to tumor metastases: a role for a3 adenosine receptor agonists
EP1383515B1 (en) Activation of natural killer cells by adenosine a3 receptor agonists
US6800639B2 (en) Pharmaceutical combination for the treatment of cancer
US6638914B1 (en) Pharmaceutical administration of adenosine agonists
JP2001509479A (ja) ヌクレオチド含有組成物
Korycka et al. Novel purine nucleoside analogues for hematological malignancies
US6790839B2 (en) Pharmaceutical administration of adenosine agonists
JP2020176071A (ja) 血液がんの新規治療法及び新規治療剤
HK1118707A (en) Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
Bashey Immunosuppression with limited toxicity: the characteristics of nucleoside analogs and anti-lymphocyte antibodies used in nonmyeloablative hematopoietic cell transplantation
US11957701B2 (en) Therapy and new therapeutic agent for blood cancer
CN101164548A (zh) 包含腺苷受体激动剂或拮抗剂的药物组合物
HK40061085A (en) Novel therapeutic method and novel therapeutic agent for hematological cancer
Korycka et al. Novel Purine Nucleoside Analogues for Hematological Malignancies

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20020309

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20030704

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20050427

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20051017

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20050427

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20051116

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20051017

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20060501

Appeal identifier: 2005101007795

Request date: 20051116

AMND Amendment
PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20051216

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20051116

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20051116

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20050727

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20030704

Patent event code: PB09011R02I

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20060102

Patent event code: PE09021S01D

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20060403

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20060501

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20051222

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20060523

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20060524

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20090406

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20100409

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20110520

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20120518

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20130502

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20130502

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20140507

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20140507

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20150922

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20150922

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20160510

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20160510

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20170510

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20170510

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20190515

Year of fee payment: 14

PR1001 Payment of annual fee

Payment date: 20190515

Start annual number: 14

End annual number: 14

PR1001 Payment of annual fee

Payment date: 20200507

Start annual number: 15

End annual number: 15

PC1801 Expiration of term

Termination date: 20210308

Termination category: Expiration of duration